Certolizumab pegol for treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA445)
NICE TA445 - Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Certolizumab pegol alone, or in combination with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults only if:
- it is used as described in the NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (recommendations 1.1 and 1.2) or
- the person has had a tumour necrosis factor (TNF)-alpha inhibitor but their disease has stopped responding after the first 12 weeks.
Certolizumab pegol is only recommended if the company provides it as agreed in the patient access scheme.
Response to certolizumab pegol should be assessed after 12 weeks of treatment. Treatment should only be continued if there is clear evidence of response (as define by NICE TA 445).
Reason for decision: